Codexis (CDXS) to Release Quarterly Earnings on Thursday

Codexis (NASDAQ:CDXS) is projected to announce its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $14.5270 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Wednesday, March 11th. The biotechnology company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.10. Codexis had a negative net margin of 62.47% and a negative return on equity of 90.51%. The company had revenue of $38.92 million during the quarter, compared to analyst estimates of $35.83 million. On average, analysts expect Codexis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Codexis Trading Up 9.6%

Shares of CDXS opened at $2.75 on Wednesday. Codexis has a 1-year low of $0.96 and a 1-year high of $3.87. The company has a 50-day moving average of $1.84 and a 200 day moving average of $1.77. The firm has a market capitalization of $249.98 million, a price-to-earnings ratio of -5.29 and a beta of 2.52. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.82 and a quick ratio of 3.75.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on CDXS shares. Stifel Nicolaus set a $5.00 price objective on shares of Codexis in a report on Thursday, March 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Codexis in a research report on Wednesday, January 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Codexis in a research report on Thursday, March 12th. Finally, Wall Street Zen downgraded shares of Codexis from a “buy” rating to a “hold” rating in a research report on Sunday. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.00.

Institutional Trading of Codexis

Large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. purchased a new stake in Codexis during the 3rd quarter worth approximately $25,000. State of Wyoming purchased a new stake in Codexis during the 2nd quarter worth approximately $25,000. CIBC Bancorp USA Inc. purchased a new stake in Codexis during the 3rd quarter worth approximately $26,000. BNP Paribas Financial Markets grew its position in Codexis by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,608 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 8,038 shares during the last quarter. Finally, Osaic Holdings Inc. grew its position in Codexis by 1,922.9% during the 2nd quarter. Osaic Holdings Inc. now owns 20,634 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 19,614 shares during the last quarter. Hedge funds and other institutional investors own 78.54% of the company’s stock.

About Codexis

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.